In part one of an interview with Cardinal Health’s Anna Catalanotto, Catalanotto outlines how early, payer-informed commercialization planning keeps cell and gene therapies accessible and financially viable.
Anna Catalanotto
Advertisement
Anna Catalanotto is director of Advanced Therapy Commercial Strategy at Cardinal Health.
Articles by Anna Catalanotto
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Ivonescimab Breakthrough Designation Highlights Progress in BTC Treatment
4
Speed-to-IND Starts with Toxicology: A Rapid-Fire Q&A with Lonza
5